News | April 17, 2026
NIFTY Pharma shows stable trend amid cautious market sentiment
Muted movement reflects consolidation phase as investors await earnings triggers
Muted movement reflects consolidation phase as investors await earnings triggers
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
The Abbreviated New Drug Application with FDA covers multiple strengths of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
